Abpro Corporation (ABP)
0.43
0.02 (4.47%)
At close: Mar 28, 2025, 3:02 PM
0.43
-0.51%
After-hours: Mar 28, 2025, 06:20 PM EDT
4.47% (1D)
| Bid | 0.41 |
| Market Cap | 22.38M |
| Revenue (ttm) | 126.84K |
| Net Income (ttm) | -17.34M |
| EPS (ttm) | -0.32 |
| PE Ratio (ttm) | -1.35 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.44 |
| Volume | 6,103 |
| Avg. Volume (20D) | 108,328 |
| Open | 0.41 |
| Previous Close | 0.41 |
| Day's Range | 0.41 - 0.45 |
| 52-Week Range | 0.41 - 13.00 |
| Beta | -0.29 |
About ABP
Abpro Holdings, Inc., a biotechnology company, engages in developing antibody therapeutics for patients with immuno-oncology, ophthalmology, and autoimmunity issues. Its platform DiversImmune addresses a bottleneck in the antibody therapeutics industry. Its lead product candidates include ABP-100 for the treatment of breast, gastric, and colorectal cancers; and ABP-201 for the treatment of vascular diseases of the eye. The company has a strategic...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 9, 2022
Employees 15
Stock Exchange NASDAQ
Ticker Symbol ABP
Website https://abpro.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ABP stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 828.72% from the latest price.
Stock Forecasts